Skip to content

Brain Cancer Health Center

Font Size

Neuroblastoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Recurrent Neuroblastoma

Tumor growth due to maturation should be differentiated from tumor progression by performing a biopsy and reviewing histology. Patients may have persistent maturing disease with metaiodobenzylguanidine (mIBG) uptake that does not affect outcome.[1] When neuroblastoma recurs in a child originally diagnosed with high-risk disease, the prognosis is usually poor despite additional intensive therapy.[2,3,4,5] However, it is often possible to gain many additional months of life for these patients with alternative chemotherapy regimens.[6,7] Clinical trials are appropriate for these patients and may be offered. Information about ongoing clinical trials is available from the NCI Web site.

Prognostic Factors for Recurrent Neuroblastoma

Recommended Related to Brain Cancer

What Is Astrocytoma?

Astrocytoma is a type of brain cancer that usually starts in the cerebrum, the largest part of your brain, but can also show up in the cerebellum (the back of the brain). It’s more common in men than women and most often shows up after age 45. There are several types of astrocytoma, and some grow faster than others. They get their name from astrocytes, the star-shaped cells where they form in the brain. About 50% of primary brain tumors are astrocytomas. Read on to learn more about symptoms,...

Read the What Is Astrocytoma? article > >

The International Neuroblastoma Risk Group Project performed a decision-tree analysis of clinical and biological characteristics (defined at diagnosis) associated with survival after relapse in 2,266 patients with neuroblastoma entered on large clinical trials in well-established clinical trials groups around the world. [2]

  • Overall survival (OS) in the entire relapse population was 20%.
  • Among patients with all stages of disease at diagnosis, MYCN amplification predicted a poorer prognosis, measured as 5-year OS.
  • Among patients diagnosed with International Neuroblastoma Staging System (INSS) stage 4 without amplification, age older than18 months and high lactate dehydrogenase (LDH) level predicted poor prognosis.
  • Among patients with MYCN amplification, stages 1 and 2 have a better prognosis than stages 3 and 4.
  • Among patients with MYCN-nonamplified who are not stage 4, patients with hyperdiploidy had a better prognosis than patients with diploidy in those younger than 18 months, while among those older than 18 months, differentiating tumors did much better than undifferentiated and poorly differentiated tumors.

Significant prognostic factors determined at diagnosis for postrelapse survival include the following:[2]

  • Age.
  • INSS stage.
  • MYCN status.
  • Time from diagnosis to first relapse.
  • LDH level, ploidy, and histologic grade of tumor differentiation (to a lesser extent).

The Children's Oncology Group (COG) experience with recurrence in low-risk and intermediate-risk neuroblastoma is that the majority of recurrences can be salvaged. The COG reported a 3-year event free survival (EFS) of 88% and an OS of 96% in intermediate-risk patients and a 5-year EFS of 89% and OS of 97% in low-risk patients.[8,9] Moreover, in most patients originally diagnosed with low-risk or intermediate-risk disease, local recurrence or recurrence in the 4S pattern may be treated successfully without hematopoietic stem cell transplantatio.

    1|2|3|4|5|6
    Next Article:

    Today on WebMD

    doctor and patient
    How to know when it’s time for home care
    doctory with x-ray
    Here are 10 to know.
     
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Lung cancer xray
    See it in pictures, plus read the facts.
     
    Malignant Gliomas
    Article
    Pets Improve Your Health
    SLIDESHOW
     
    Headache Emergencies
    Video
    life after a brain tumor
    VIDEO
     

    Would you consider trying alternative or complementary therapies?


    WebMD Special Sections